TORONTO, July 24, 2019 /PRNewswire/ - Liberty Health Sciences Inc. (LHS.CN) (OTCQX: LHSIF) www.libertyhealthsciences.com ("Liberty" or the "Company"), a provider of high quality cannabis, announced today that it has the second highest sales of smokable marijuana in the state of Florida with 16 dispensaries open. Liberty was one of the first companies in the state to provide smokable medical marijuana in all of its dispensaries when bill (SB 182) was signed into law on March 8, 2019 revoking a ban on smoking medical marijuana.
Flower sales of Liberty and Papa's Herb brands is the driving factor of the significant market success for this growing category and the Company continues to cultivate brand recognition and attract a constant stream of new patients.
Senate Bill 182 permits qualified patients to receive up to 2.5 ounces of whole flower (smokable) cannabis every 35 days. As of July 19, 2019, the Office of Medical Marijuana Use (OMMU) reports there are 246,079 qualified patients and 2,386 physicians in Florida.
With the passing of Amendment 2 and the subsequent Senate Bill 8A in 2017, Florida legalized medical cannabis for 10 qualifying conditions: cancer, epilepsy, glaucoma, HIV, AIDS, Post Traumatic Stress Disorder (PTSD), Amyotrophic Lateral Sclerosis (ALS), Crohn's Disease, Parkinson's Disease, and Multiple Sclerosis (MS), as well as "medical conditions of the same kind or class as or comparable to the above qualifying conditions," such as Generalized Anxiety Disorder.
"Our outstanding results are directly driven by the strategy that we have been implementing," said Victor Mancebo, Interim Chief Executive Officer of Liberty. "This is a very proud moment for the Liberty team as we outranked other MMTC's in Florida. Most importantly, we continue to provide all Florida patients the medicine that they are seeking. As we aggressively continue to grow our footprint and product portfolio, we expect to amplify our results and progressively increase the offerings for our patients."
Liberty Health Sciences is quickly becoming a leading cultivator and distributor of premium cannabis products through low-cost production techniques and high-end dispensary design. The Company continues to successfully expand its house flower brand of products and prides itself in offering access to the best brands in any category, including PAX, Mary's Medicinals, Pretty Pistil, and Papa's Herb to name a few.
Liberty currently operates 16 dispensaries across Florida, with the Boca Raton location celebrating its opening on July 22, where it serves a population of approximately 100,000. Next month Liberty plans to open three new dispensaries in Panama City, Pensacola, and Orlando, joining the list of store locations listed below:
• Dania Beach
• North Miami
• Port St. Lucie
• Palm Harbor
• St. Petersburg
• Orange Park
• Tampa (Hyde Park)
• Winter Haven
• Merritt Island
• Cape Coral
• Boca Raton
• Bonita Springs
Patients may place an order online at www.libertyhealthsciences.com for in-store pick-up or free delivery. Liberty also offers patients free statewide delivery.
About Liberty Health Sciences Inc.
Liberty is the cannabis provider committed to providing a trusted, high quality cannabis experience based on our genuine care for all cannabis users and a focus on operational excellence from seed to sale. Liberty's measured approach to expansion opportunities is focused on maximizing returns to shareholders, while keeping consumers' well-being at the forefront of what we do. For more information, please visit: www.libertyhealthsciences.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "believe", "plan", "intend" or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the Company's production capabilities, expectations concerning the receipt of all necessary approvals from the Florida Department of Health, expectations concerning the opening of new dispensaries and the expansion of its greenhouse space, and the Company's future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
View original content to download multimedia:http://www.prnewswire.com/news-releases/liberty-health-sciences-ranks--2-in-flower-sales-in-florida-300889919.html